Abstract: The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of NK-1 receptor antagonist compounds; to methods for the discovery of molecules that are potential NK-1 receptor antagonist compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist molecules which do not possess significant potency towards CYP2D6.
Abstract: Compounds of the formula (I):
wherein A, Y, R, X, R1, R2, R3 and R4 are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders involving nerve damage.
Type:
Grant
Filed:
January 23, 2002
Date of Patent:
May 13, 2003
Assignee:
Pfizer Inc
Inventors:
Mark Ian Kemp, Michael John Palmer, Mark Allen Sanner, Martin James Wythes
Abstract: A shaving razor has a blade carrier, which may be part of a replaceable blade cartridge, pivotally supported by a main component or handle assembly, the main component and the blade carrier having cooperating convex and concave arcuate bearing surfaces whereby the carrier is movable about the pivot axis by sliding movement of the convex and concave bearing surfaces over one another, and a spring mechanism both holds the convex and concave bearing surfaces in engagement with one another and resiliently biases the carrier in one direction about the pivot axis toward a limit position.
Abstract: This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula:
where Y is ═C(R1a)— or —[N□(O)k]— where k is 0 or 1;
G1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G1 is not a discontinuous or restricted biaryl moiety as defined under G2; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; —G2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted bi
Type:
Grant
Filed:
January 31, 2002
Date of Patent:
May 6, 2003
Assignee:
Pfizer Inc
Inventors:
Anthony Marfat, Michael William McKechney
Abstract: This invention is directed to compounds of the formula
and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.
Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.
Abstract: The invention relates to pharmaceutical compositions and methods useful in the treatment of obesity which methods comprise administering to animal, including a human or companion animal, in need of such treatment an effective amount of a compound of the structural formula
or a pharmaceutically acceptable salt, racemate or enantiomer thereof, wherein
R is hydroxy, esterified hydroxy or etherified hydroxy;
R1 and R2 are, independently, halogen, trifluoromethyl or lower alkyl;
R3 is halogen, trifluoromethyl, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkyl-lower alkyl, carbocyclic arylmethyl, carbocyclic aroyl, carbocyclic arylhydroxymethyl; or
R3 is the radical
wherein
R8 is hydrogen, lower alkyl, aryl, cycloalkyl, aryl-lower alkyl or cycloalkyl-lower alkyl;
R9 is hydroxy or acyloxy; R10 is hydrogen or lower alkyl; or R9 and R10, taken together with the carbon atom to which they are attached, form a carbonyl group;
R4 is hydrogen, halogen, trifluorom
Type:
Grant
Filed:
October 16, 2001
Date of Patent:
April 29, 2003
Assignee:
Pfizer Inc.
Inventors:
Peter Cornelius, Diane Hargrove, Bradley P. Morgan, Andrew G. Swick
Abstract: A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.
Type:
Grant
Filed:
February 16, 2001
Date of Patent:
April 29, 2003
Assignee:
Pfizer Inc.
Inventors:
Joyce A. Sutcliffe, Judith Lee Treadway
Abstract: This application is directed to a compound of Formula I
wherein a, X, R1, R2, R3 and R4 are as defined herein, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.
Abstract: This invention relates to compounds of the formula 1
and to pharmaceutically acceptable salts, prodrugs, and solvates thereof wherein X1, R1, R2, R8, R9 and R10 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
Type:
Grant
Filed:
February 26, 2001
Date of Patent:
April 29, 2003
Assignee:
Pfizer Inc.
Inventors:
Takushi Kaneko, William Thomas McMillen, Wei-Guo Su, Hongjuan Zhao
Abstract: This invention relates to novel methods of measuring the activity and/or levels of ABCA1 protein, including the use of acceptors of ABCA1 substrates, as well as methods involving the measurement of ABCA1 mRNA and protein levels.
Abstract: Razor heads comprising at least one blade and a plurality of guard elements over the leading edge at a plurality of intermediate portions. According to preferred embodiments, the guard elements are integrally molded with at least one or more of a blade support, spacer element(s), forward guard member and cap member. The use of integrally molded guard elements facilitate efficient, quicker and less expensive manufacturing, provide greater design flexibility, and provide greater blade stability. Additionally, in preferred embodiments, when the molded guard elements are aligned with spacers, these guard elements do not interfere with the rinsability of the razor head. The intermediate guard elements also provide additional sites for the placement of shaving aids and other skin flow control materials such as materials having a relatively high coefficient of friction.
Type:
Grant
Filed:
July 28, 2000
Date of Patent:
April 22, 2003
Assignee:
Warner-Lambert Company
Inventors:
David F. Rivers, Andrew Pennella, Paul D. Richard
Abstract: This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I,
wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.
Abstract: This invention provides a RP-HPLC method, for the determination of logPoct values, which combines ease of operation and high accuracy, and which has been shown to work for a set of 36 molecules largely comprised of drugs. The general features of the method are: i) compound sparing (≦1 mL of a 30-50 &mgr;g/mL solution needed), ii) rapid determinations (20 minutes on average), iii) low sensitivity to impurities, iv) wide lipophilicity range (6 logPoct units), v) good accuracy, vi) excellent reproducibility. A linear free energy relationship (LFER) analysis, based on solvation parameters, shows that the method encodes the same information obtained from a shake-flask logPoct determination. The value generated via this method is referred to as ElogPoct.
Type:
Grant
Filed:
February 13, 2001
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc.
Inventors:
Franco Lombardo, Marina Y. Shalaeva, Karl A. Tupper
Abstract: A mixture comprising:
a) virginiamycin;
b) a pharmaceutically acceptable and substantially anhydrous wetting agent including sodium lauryl sulfate;
c) a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3 0 to about 7.0 when said mixture is added to water; and
d) from about 0.5 weight percent to about 10 0 weight percent colloidal silicon dioxide,
wherein the ratio of the weight percent of (b) to the weight percent of (a) percent by weight is at least about 1.5:1.
The mixture is designed to be added to water to produce a stable suspension of the virginiamycin, which can then be applied to, for example, feed grain.
Type:
Grant
Filed:
October 24, 2001
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc.
Inventors:
James W. Carson, Frederic W. Chapin, Charles H. Fahrenholz
Abstract: The present invention is directed to methods for stimulating the motility of the gastrointestinal system in a patient which comprises administering a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug. More particularly, the present invention provides methods for stimulating the motility of the gastrointestinal system in a patient which comprises administering a compound of Formula I:
a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.
Abstract: A compound of the formula
or the pharmaceutically acceptable salt thereof; wherein R1, R2, R3 and R4 are as defined above useful to treat inflammation and other immune disorders.
Abstract: The present invention relates to compounds of the formula 1
and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
Type:
Grant
Filed:
March 9, 2001
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc
Inventors:
Eric R. Larson, Mark C. Noe, Thomas G. Gant
Abstract: A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropylmethylcellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP). The compositions having improved solubility, hence bioavailability, in the small intestine; Processes for testing such compositions, and methods of using such compositions. The compositions comprise the basic drug, zwitterion, or salt and one or more of the aforementioned polymers. The invention further relates to a method for increasing the bioavailability of a basic or a zwitterionic drug comprising co-administering the basic drug, the zwitterionic drug, or the salt, with one or more of the aforementioned polymers.
Type:
Grant
Filed:
January 31, 2000
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc
Inventors:
William J. Curatolo, James A. S. Nightingale, Ravi M. Shanker, Steven C. Sutton
Abstract: This invention relates to pharmaceutical compositions comprising combinations of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug and a SDI, a prodrug thereof or a pharmaceutically acceptable salt of said SDI or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.